Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer.
Peressini M, Garcia-Campelo R, Massuti B, Martí C, Cobo M, Gutiérrez V, Dómine M, Fuentes J, Majem M, de Castro J, Córdoba JF, Diz MP, Isla D, Esteban E, Carcereny E, Vila L, Moreno-Vega A, Ros S, Moreno A, García FJ, Huidobro G, Aguado C, Cebey-López V, Valdivia J, Palmero R, Lianes P, López-Brea M, Vidal OJ, Provencio M, Arriola E, Baena J, Herrera M, Bote H, Molero M, Adradas V, Ponce-Aix S, Nuñez-Buiza A, Ucero Á, Hernandez S, Lopez-Rios F, Conde E, Paz-Ares L, Zugazagoitia J. Peressini M, et al. Among authors: palmero r. Clin Cancer Res. 2024 Jul 15;30(14):3036-3049. doi: 10.1158/1078-0432.CCR-24-0104. Clin Cancer Res. 2024. PMID: 38630755 Clinical Trial.
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
Provencio M, Nadal E, González-Larriba JL, Martínez-Martí A, Bernabé R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, Reguart N, de Castro J, Mosquera J, Cobo M, Aguilar A, López Vivanco G, Camps C, López-Castro R, Morán T, Barneto I, Rodríguez-Abreu D, Serna-Blasco R, Benítez R, Aguado de la Rosa C, Palmero R, Hernando-Trancho F, Martín-López J, Cruz-Bermúdez A, Massuti B, Romero A. Provencio M, et al. Among authors: palmero r. N Engl J Med. 2023 Aug 10;389(6):504-513. doi: 10.1056/NEJMoa2215530. Epub 2023 Jun 28. N Engl J Med. 2023. PMID: 37379158 Clinical Trial.
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
Reguart N, Rosell R, Cardenal F, Cardona AF, Isla D, Palmero R, Moran T, Rolfo C, Pallarès MC, Insa A, Carcereny E, Majem M, De Castro J, Queralt C, Molina MA, Taron M. Reguart N, et al. Among authors: palmero r. Lung Cancer. 2014 May;84(2):161-7. doi: 10.1016/j.lungcan.2014.02.011. Epub 2014 Mar 2. Lung Cancer. 2014. PMID: 24636848 Clinical Trial.
Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.
Moran T, Taus A, Arriola E, Aguado C, Dómine M, Rueda AG, Calles A, Cedrés S, Viñolas N, Isla D, Palmero R, Sereno M, Diaz V, Juan O, Marsé R, Martorell PM, Sánchez Torres JM; Study Group for the Uncommon EGFR Mutations in Spain. Moran T, et al. Among authors: palmero r. Clin Lung Cancer. 2020 Sep;21(5):428-436.e2. doi: 10.1016/j.cllc.2020.04.011. Epub 2020 Apr 25. Clin Lung Cancer. 2020. PMID: 32461037
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program.
Bernabé-Caro R, Garrido P, García-Campelo R, Palmero R, Artal Á, Bayona C, Rodríguez-Abreu D, López-Brea M, Paredes A, Vicente D, Sánchez Torres JM, Majem M, Diz P, Gordo R, Coca M, de Castro J. Bernabé-Caro R, et al. Among authors: palmero r. Oncotarget. 2022 Jun 15;13:812-827. doi: 10.18632/oncotarget.28244. eCollection 2022. Oncotarget. 2022. PMID: 35720977 Free PMC article.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Rosell R, et al. Among authors: palmero r. Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26. Lancet Oncol. 2012. PMID: 22285168 Clinical Trial.
Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients.
Vidal J, Clavé S, de Muga S, González I, Pijuan L, Gimeno J, Remón J, Reguart N, Viñolas N, Gironés R, Bernet L, Majem M, Bosch-Barrera J, Porta R, Alonso N, Palmero R, Taus A, Albanell J, Espinet B, Salido M, Arriola E. Vidal J, et al. Among authors: palmero r. J Thorac Oncol. 2014 Dec;9(12):1816-20. doi: 10.1097/JTO.0000000000000361. J Thorac Oncol. 2014. PMID: 25393795 Free article.
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Moran T, Palmero R, Provencio M, Insa A, Majem M, Reguart N, Bosch-Barrera J, Isla D, Costa EC, Lee C, Puig M, Kraemer S, Schnell D, Rosell R. Moran T, et al. Among authors: palmero r. Lung Cancer. 2017 Jun;108:154-160. doi: 10.1016/j.lungcan.2017.03.009. Epub 2017 Mar 22. Lung Cancer. 2017. PMID: 28625629 Clinical Trial.
Screening for epidermal growth factor receptor mutations in lung cancer.
Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M; Spanish Lung Cancer Group. Rosell R, et al. Among authors: palmero r. N Engl J Med. 2009 Sep 3;361(10):958-67. doi: 10.1056/NEJMoa0904554. Epub 2009 Aug 19. N Engl J Med. 2009. PMID: 19692684 Free article.
Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.
Palmero R, Taus A, Viteri S, Majem M, Carcereny E, Garde-Noguera J, Felip E, Nadal E, Malfettone A, Sampayo M, Riva F, Nagy RJ, Lanman RB, Faull I, Dix D, Karachaliou N, Rosell R. Palmero R, et al. JCO Precis Oncol. 2021 Nov;5:93-102. doi: 10.1200/PO.20.00241. JCO Precis Oncol. 2021. PMID: 34994593
50 results